Levofloxacin-associated leukocytoclastic vasculitis with bullous lesions in a man treated for a diabetic foot infection
Abstract
Levofloxacin and other fluoroquinolones are widely used antibiotics, though they can cause rare immune-mediated adverse events. We report a man in his late 50 s with long-standing type 2 diabetes mellitus and a new plantar foot wound who was prescribed oral levofloxacin for presumed soft-tissue infection. Within 48-72 h of starting levofloxacin, he developed rapidly progressive palpable purpura that began on the upper extremities and spread to the lower extremities up to the thighs, with intense pruritus, migratory arthralgias, and bullous lesions on the distal lower extremities and right upper extremity. He had no mucosal involvement and no pulmonary or gastrointestinal symptoms. Dermatologic evaluation favored small-vessel vasculitis; systemic corticosteroids were initiated and the patient was transferred for further management. Skin biopsy demonstrated leukocytoclastic vasculitis with leukocytoclasis and fibrinoid necrosis of superficial dermal vessels. Direct immunofluorescence showed perivascular IgG and C3 without IgA deposition. Workup revealed elevated inflammatory markers, elevated serum IgA, positive p-ANCA with negative MPO and PR3, probable mixed cryoglobulins, and mild hematuria and proteinuria without casts; nephrology assessed low likelihood of clinically significant renal vasculitis. Levofloxacin was discontinued and a short corticosteroid taper was completed, with steady improvement of rash and stable renal function. This case highlights the recognition and…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.